German health insurers, under pressure to cut costs amid reforms, are considering whether to restrict prescription guidelines for Sanofi-Aventis's blood thinner Plavix in a move that could harm the drug's sales.
The German Institute for Quality and Efficiency in Healthcare (IQWiG) said clopidogrel, marketed by Sanofi-Aventis and Bristol-Myers Squibb as Plavix or Iscover, offered no benefits over aspirin when used alone as a preventative treatment for conditions resulting from arterial diseases.
Source
No comments:
Post a Comment